Response to paper by Binkowska et al . Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy.

AMA Douxfils J, Foidart J, Gaspard U, et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny. 2023;22(2):117-119. doi:10.5114/pm.2023.128815. APA Douxfils, J., Foidart, J., Gaspard, U., Chatel, G., Taziaux, M., & Jost, M. et al. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny, 22(2), 117-119. https://doi.org/10.5114/pm.2023.128815 Chicago Douxfils, Jonathan, Jean-Michel Foidart, Ulysse Gaspard, Guillaume Chatel, Mélanie Taziaux, Maud Jost, and Céline Gérard et al. 2023. "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy". Menopause Review/Przegląd Menopauzalny 22 (2): 117-119. doi:10.5114/pm.2023.128815. Harvard Douxfils, J., Foidart, J., Gaspard, U., Chatel, G., Taziaux, M., Jost, M., Gérard, C., and Morimont, L. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny, 22(2), pp.117-119. https://doi.org/10.5114/pm.2023.128815 MLA Douxfils, Jonathan et al. "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy." Menopause Review/Przegląd Menopauzalny, vol. 22, no. 2, 2023, pp. 117-119. doi:10.5114/pm.2023.128815. Vancouver Douxfils J, Foidart J, Gaspard U, Chatel G, Taziaux M, Jost M et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny. 2023;22(2):117-119. doi:10.5114/pm.2023.128815.